The Clinical Diagnosis Meaning of MIF in Coronary Heart Disease
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine that promote the inflammatory response.In animal studies, it has been found that MIF is released in the ischaemic heart, promoting glucose uptake and protecting the heart from ischaemia-reperfusion injury.The MIF concentration, influenced by age and myocardial ischemia, have different impact on myocardial functional recovery after ischemia.Therefore, the purpose of this experiment is to study the clinical significance of MIF in patients with coronary heart disease.
| Condition |
|---|
|
Coronary Heart Disease |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | MIF Gene Polymorphism in Coronary Heart Disease：Clinical Meaning |
- Comparison between coronary-artery-disease group and non-coronary-artery-disease group on MIF concentration [ Time Frame: Before surgery 5 minutes ] [ Designated as safety issue: Yes ]Participants will be extracted 3ml blood before surgery 5 minutes,detection MIF concentration on two groups.The experimental group will be higher than control group.
- Comparison the change of MIF before and after PCI at the patients who are acute coronary syndromes and stable ischemic heart disease [ Time Frame: 3 times including before surgery 5 minutes, 5 minutes after the opening of the balloon and after surgery 5 minutes ] [ Designated as safety issue: Yes ]PCI are extracted 3 times including before suergery 5 minutes , 5 minutes after the opening of the balloon and after surgery 5 minutes ,and detection MIF concentration .
Biospecimen Retention: Samples Without DNA
The biospecimen is blood that taken from cubital vein.
| Estimated Enrollment: | 336 |
| Study Start Date: | May 2012 |
| Estimated Study Completion Date: | July 2013 |
| Estimated Primary Completion Date: | July 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
coronary-artery-disease group
Participants, who are diagnosed as coronary-artery-disease which including acute coronary syndromes and stable ischemic heart disease, will receive at least one stent.
|
|
non-coronary-artery-disease group
Participants, who are diagnosed as non-coronary-artery-disease without acute coronary syndromes and stable ischemic heart disease, will not receive stent.
|
Detailed Description:
MIF is a pleiotropic cytokine that promote the inflammatory response. MIF is expressed in several cell types,including monocytes/macrophages, vascular smooth muscle and cardiomyocytes, and is released on stimulation from pre-formed storage pools. A foreign study reported that MIF had demonstrated to offer protection from I/R-injury by activating adenosine monophosphate-activated protein kinase (AMPK) and inhibiting c-Jun Nterminal kinase (JNK)-induced apoptosis of cardiomyocytes. In addition, animal experiments showed that MIF was reduced in aged heart compared with young heart. Coronary heart disease is a chronic ischemic disease, in which MIF may play as a protective factor during the whole procedure.
We observed individuals who will be taking coronary angiography during the hospitalization. Individuals will be assigned to coronary-artery-disease group, which included acute coronary syndromes and stable ischemic heart disease, or non-coronary-artery-disease group, according to coronary angiography. All participants will be extracted 3ml blood sample 5 minutes before coronary angiography. Coronary-artery-disease group will be taken another two blood samples, 5 minutes after the opening of the balloon and 5 minutes after the stents have been implanted, respectively.
Eligibility| Ages Eligible for Study: | 20 Years to 90 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Second Hispital of Wenzhou Medical College outpatient and inpatient
Inclusion Criteria:
Control group:
- enroll individuals who confirmed by coronary angiography without coronary heart
- The age between 20 and 80 years old.
- Alanine aminotransferase(ALT):10-55U/L, Aspartate aminotransferase(AST):0-60U/L
- Glucose(GLU-S):3.9-6.1mmol/L
- Triglycerides(TRIG):0.56-1.7mmol/L, cholesterol(CHOL):3.1-5.2mmol/L, High density lipoprotein(HDL):0.78-1.96mmol/L, High density lipoprotein(LDL):2.07-3.1mmol/L
Experimental group:
- enroll individuals who confirmed by coronary angiography for coronary heart
- The age between 20 and 80 years old.
- ALT:10-55U/L,AST:0-60U/L
- GLU-S:3.9-6.1mmol/L
- TRIG:0.56-1.7mmol/L,CHOL:3.1-5.2mmol/L,HDL:0.78-1.96mmol/L,LDL:2.07-3.1mmol/L
Exclusion Criteria:
- Inflammatory diseases,such as rheumatoid arthritis,sepsis,asthma and acute respiratory distress syndrome.
- Diabetes
Contacts and Locations| Contact: JiFei Tang, Master | 13676587343 | 454725192@qq.com |
| China, Zhejiang | |
| Second Hispital of Wenzhou Medical College | Recruiting |
| Wenzhou, Zhejiang, China, 325000 | |
| Contact: JiFei Tang, MD 13676587343 454725192@qq.com | |
| Contact: Kangting Ji, MD 13676403180 heywyi@163.com | |
| Principal Investigator: | Jifei Tang, MD | Wenzhou Medical College |
More Information
No publications provided
| Responsible Party: | JiFei Tang, Director, Wenzhou Medical College |
| ClinicalTrials.gov Identifier: | NCT01750502 History of Changes |
| Other Study ID Numbers: | wenzhouhp |
| Study First Received: | November 24, 2012 |
| Last Updated: | December 12, 2012 |
| Health Authority: | China: Ethics Committee |
Additional relevant MeSH terms:
|
Coronary Artery Disease Myocardial Ischemia Coronary Disease Heart Diseases |
Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases |
ClinicalTrials.gov processed this record on May 16, 2013